BIOMARIN AND ALLIANT IN LICENSING DEAL

BioMarin Pharmaceutical has agreed to license North American rights of its asthma drug Orapred to Alliant Pharmaceuticals. Under the terms of the agreement, BioMarin will receive payments and royalties based on the product's approval, launch and level of sales. BioMarin will retain commercial rights outside of North America.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=BD64B12D-E94F-41CE-98D5-5E77C730EF62)